(Q26782089)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26437390%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

29 October 2020

Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26437390%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

29 October 2020

familial amyloid neuropathy

1 reference

29 October 2020

1 reference

29 October 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26437390%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Hartmut H-J Schmidt

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26437390%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Gursimran Chandhok

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26437390%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

language of work or name

English

0 references

publication date

30 September 2015

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26437390%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

29 October 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26437390%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

29 October 2020

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26437390%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26437390%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

17944-17975

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26437390%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

26 February 2020

copyright license

1 reference

29 October 2020

0 references

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Therapeutic oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Non-coding RNAs: regulators of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

RNA therapeutics: beyond RNA interference and antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Antisense mediated splicing modulation for inherited metabolic diseases: challenges for delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

De-repressing LncRNA-Targeted Genes to Upregulate Gene Expression: Focus on Small Molecule Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Liver as a target for oligonucleotide therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Current prospects for RNA interference-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Antisense technology: an emerging platform for cardiovascular disease therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Genetics of liver disease: From pathophysiology to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Transthyretin familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Transthyretin-related familial amyloidotic polyneuropathy-Progress in Kumamoto, Japan (1967-2010)-.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

The molecular biology and clinical features of amyloid neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Nutritional assessment (protein nutriture).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Transthyretin amyloidosis: a tale of weak interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Molecular mechanisms of amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

The preaggregated state of an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the amyloidogenic state

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Revised transthyretin Ile 122 allele frequency in African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

A Danish kindred with familial amyloid cardiomyopathy revisited: Identification of a mutant transthyretinmethionine111 variant in serum from patients and carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Vitreous Amyloidosis as the Presenting Symptom of Familial Amyloid Polyneuropathy TTR Val30Met in a Portuguese Patient

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Transthyretin-related amyloidoses and the heart: a clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Liver transplantation for familial amyloidotic polyneuropathy: Impact on Swedish patients' survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Variant transthyretin in blood circulation can transverse the blood-cerebrospinal barrier: qualitative analyses of transthyretin metabolism in sequential liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Transthyretin (TTR) cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Early liver transplantation improves familial amyloidotic polyneuropathy patients' survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Inhibition of transthyretin-met30 expression using Inosine(15.1)-Hammerhead ribozymes in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Fluorescence microscopic comparison of the binding of phosphodiester and phosphorothioate (antisense) oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum, and the nuclear interior

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Intracellular traffic of oligodeoxynucleotides in and out of the nucleus: effect of exportins and DNA structure

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Ribonuclease H: the enzymes in eukaryotes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

How does RNase H recognize a DNA.RNA hybrid?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Insights into RNA/DNA hybrid recognition and processing by RNase H from the crystal structure of a non-specific enzyme-dsDNA complex

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Properties of cloned and expressed human RNase H1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Evaluation of multiple-turnover capability of locked nucleic acid antisense oligonucleotides in cell-free RNase H-mediated antisense reaction and in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

The high binding affinity of phosphorothioate-modified oligomers for Ff gene 5 protein is moderated by the addition of C-5 propyne or 2'-O-methyl modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

CD, absorption and thermodynamic analysis of repeating dinucleotide DNA, RNA and hybrid duplexes [d/r(AC)]12.[d/r(GT/U)]12 and the influence of phosphorothioate substitution

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Antisense technologies. Improvement through novel chemical modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Systemic administration of PRO051 in Duchenne's muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Locked nucleic acid oligomers as handles for single molecule manipulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Atomistic investigation of the effect of incremental modification of deoxyribose sugars by locked nucleic acid (β-D-LNA and α-L-LNA) moieties on the structures and thermodynamics of DNA-RNA hybrid duplexes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Conformationally locked nucleosides. Synthesis and hybridization properties of oligodeoxynucleotides containing 2',4'-C-bridged 2'-deoxynucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Design of antisense oligonucleotides stabilized by locked nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Increased uptake of antisense oligonucleotides by delivery as double stranded complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Mipomersen sodium: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Is mipomersen ready for clinical implementation? A transatlantic dilemma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Strategies for silencing human disease using RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Hepatic RNA Interference: Delivery by Synthetic Vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Role for a bidentate ribonuclease in the initiation step of RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Molecular mechanisms of RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

RNA interference is mediated by 21- and 22-nucleotide RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Functional siRNAs and miRNAs Exhibit Strand Bias

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Argonaute2 is the catalytic engine of mammalian RNAi

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Crystal structure of Argonaute and its implications for RISC slicer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Molecular basis for target RNA recognition and cleavage by human RISC.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Modeling RNA interference in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

A microRNA in a multiple-turnover RNAi enzyme complex

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Chromatin-associated RNA interference components contribute to transcriptional regulation in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Biological barriers to therapy with antisense and siRNA oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

siRNA function in RNAi: a chemical modification analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Phosphorothioate nucleotides and oligonucleotides - recent progress in synthesis and application

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Tolerance for mutations and chemical modifications in a siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Expression profiling reveals off-target gene regulation by RNAi

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Off-target effects by siRNA can induce toxic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Activation of the interferon system by short-interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Activation of the mammalian immune system by siRNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

RNAi-mediated gene silencing in non-human primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Target mRNA inhibition by oligonucleotide drugs in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Is there a future for cell-penetrating peptides in oligonucleotide delivery?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Dynamin and receptor-mediated endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Phosphorothioate-stimulated uptake of short interfering RNA by human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Oligonucleotide conjugates for therapeutic applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Lipid nanoparticles improve activity of single-stranded siRNA and gapmer antisense oligonucleotides in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Covalent conjugation of oligonucleotides with cell-targeting ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Cellular uptake of antisense oligonucleotides after complexing or conjugation with cell-penetrating model peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Intracellular delivery of oligonucleotide conjugates and dendrimer complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Lipid nanoparticle delivery systems for siRNA-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Synthesis and in vitro inhibition properties of siRNA conjugates carrying glucose and galactose with different presentations

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Transthyretin Antisense Oligonucleotides Lower Circulating RBP4 Levels and Improve Insulin Sensitivity in Obese Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Oral delivery of small RNA and DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Genotype – phenotype correlation in FAP

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

Familial Amyloidotic Polyneuropathy: domino liver transplantation

21 January 2018

1 reference

12 December 2020

Nuclear gene targeting using negatively charged liposomes

1 reference

12 December 2020

Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats

1 reference

12 December 2020

Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides

1 reference

12 December 2020

RNA interference targeting Fas protects mice from fulminant hepatitis

1 reference

12 December 2020

Gene silencing by systemic delivery of synthetic siRNAs in adult mice

1 reference

12 December 2020

Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

1 reference

12 December 2020

Antisense treatments for biothreat agents.

1 reference

12 December 2020

Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients

1 reference

12 December 2020

Antisense oligonucleotide pharmacokinetics and metabolism

1 reference

12 December 2020

Polerovirus protein P0 prevents the assembly of small RNA-containing RISC complexes and leads to degradation of ARGONAUTE1

1 reference

12 December 2020

Breaking down the barriers: siRNA delivery and endosome escape

1 reference

12 December 2020

Antisense oligonucleotide therapy for TTR amyloidosis

1 reference

12 December 2020

Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo

1 reference

12 December 2020

A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology

1 reference

12 December 2020

Genetic variation in the non-coding genome: Involvement of micro-RNAs and long non-coding RNAs in disease

1 reference

12 December 2020

Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration

1 reference

12 December 2020

Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing

1 reference

12 December 2020

Presence of an abnormal transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy

1 reference

12 December 2020

The surface content of asialoglycoprotein receptors on isolated hepatocytes is reversibly modulated by changes in temperature

1 reference

12 December 2020

The asialoglycoprotein receptor: relationships between structure, function, and expression

1 reference

12 December 2020

Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation

1 reference

12 December 2020

Characterization and subcellular localization of ribonuclease H activities from Xenopus laevis oocytes.

1 reference

12 December 2020

Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding.

1 reference

12 December 2020

Pharmacokinetic properties of several novel oligonucleotide analogs in mice

1 reference

12 December 2020

Transthyretin is not essential for thyroxine to reach the brain and other tissues in transthyretin-null mice.

1 reference

12 December 2020

In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.

1 reference

12 December 2020

Active nuclear import of single-stranded oligonucleotides and their complexes with non-karyophilic macromolecules.

1 reference

12 December 2020

Efficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES201017944

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.3390/MOLECULES201017944

2 references

Consolidated OpenCitations Corpus – April 2017

3754440

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26437390%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

3754440

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26437390%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

2 references

Consolidated OpenCitations Corpus – April 2017

3754440

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26437390%20AND%20SRC:MED&resulttype=core&format=json